9/28/2026
Psyence Biomedical secures $1.3M ibogaine licensing deal
Texas subsidiary gains exclusive U.S. rights to PsyLabs' ibogaine
Topic archive
warwick corden lloyd
7 stories
9/28/2026
Psyence secures exclusive U.S. ibogaine license
Texas subsidiary gains rights to ibogaine hydrochloride for drug development.
9/23/2026
Psyence BioMed announces ibogaine investment and trial plans
Psyence BioMed to invest $5M in PsyLabs, plans Texas ibogaine trial.
9/14/2026
Psyence BioMed forms Texas entity for U.S. ibogaine research
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
8/19/2026
Psyence BioMed supports U.S. push for ibogaine development
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Psyence BioMed backs Trump ibogaine initiative
Company aligns with U.S. efforts to advance ibogaine research.
8/7/2026
Psyence Biomedical unveils strategic plans in new investor presentation
Psyence Biomedical outlines its focus on psychedelic therapeutics for mental health in a recent investor update.